21.11.2024
Nvidia continues to grow explosively thanks to AI boom + DATAGROUP with preliminary figures TOP + Novartis aims for slightly stronger growth in the medium term
The AI boom is a boon for the chip group Nvidia $NVDA (-2,33%) has become a goldmine - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The AI boom has become a goldmine for the chip company Nvidia - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The next chip generation is on its way!
DATAGROUP $D6H (-2,93%) reaches the upper end of guidance according to preliminary figures for FY 2023/2024
- Total revenue in FY 2023/2024 up 6.0 % to EUR 527.6m
- Continued strong development in CORBOX core business
- Continued increase in quarterly sales: sales in the fourth quarter of 2023/2024 up 14.8% on the previous year, organic growth of around 8.0
- EBIT in the 2023/2024 financial year also at the upper end of the forecast at EUR 45.8 million
- EBIT margin at 8.7% as planned, characterized by investments in future technologies
- Comprehensive package adopted to increase shareholder value
The Swiss pharmaceutical group Novartis $NOVN (+2,16%) expects slightly more growth in the medium term than before following its reorganization. In the period from 2023 to 2028, Group sales are expected to increase by an average of 6 percent annually instead of the previously targeted 5 percent, the company announced on Thursday at an investor day. With the new forecast, the Group's top management led by CEO Vasant Narasimhan is relying on the strong growth momentum of the brands already on the market, among other things. Together, these brands have the potential to generate more than 3 to more than 8 billion US dollars a year at peak times. In addition, the Group is about to submit marketing authorization applications for more than 15 additional drugs. The Basel-based company also points to a well-filled research pipeline with more than 30 drugs in testing, which should enable sales growth in the mid-single-digit range even after 2029. Meanwhile, Novartis is still aiming for an adjusted operating margin of more than 40 percent by 2027. The Swiss pharmaceutical giant has now transformed itself into a company specializing purely in innovative medicines. The focus is on the four therapeutic areas of cardiovascular, renal and metabolic diseases, immunology, neurology and oncology
Thursday: Stock market dates, economic data, quarterly figures
ex-dividend of individual stocks
Microsoft USD 0.83
Vodafone Group USD 0.02
Applied Materials USD 0.40
Quarterly figures / company dates USA / Asia
12:30 PDD Holdings quarterly figures
14:00 GE Healthcare Technologies Investor Day
No time specified: Intuit | Gap | Deere & Co quarterly figures | ResMed AGM
Quarterly figures / Company dates Europe
07:00 Julius Baer Group 10 months results
07:30 CTS Eventim quarterly figures
08:00 DFV Deutsche Familienversicherung AG Quarterly figures
Economic data
- 08:00 DE: Insolvencies
- 08:45 FR: Business Climate Index November PROGNOSIS: 97 previous: 97
- 12:00 TR: Turkish Central Bank, outcome of the Monetary Policy Council meeting Key interest rate FORECAST: n/a previously: 50.00%
- 14:30 US: Initial jobless claims (week) FORECAST: 220,000 Previous: 217,000
- 14:30 US: Philadelphia Fed Index November PROJECTED: 8.2 PREVIOUS: 10.3
- 16:00 US: Leading Indicators Index October FORECAST: -0.4% yoy previous: -0.5% yoy
- 16:00 US: Existing Home Sales October FORECAST: +2.9% yoy previous: -1.0% yoy
- 16:00 EU: Eurozone Consumer Confidence Index (flash estimate) November FORECAST: -12.1 previous: -12.5
